Ridge Biotechnologies, Inc.

Ridge Biotechnologies, Inc. , based in the US, specializes in AI-driven enzyme and targeted drug design, focusing on innovative therapeutics that address complex medical challenges in the biopharmaceutical field. Founded in 2024 in Palo Alto, US, Ridge Biotechnologies, Inc. is dedicated to advancing biotechnology solutions.

The company has undergone no major pivots or operational changes since its inception. The latest funding round took place on September 9, 2025, when Ridge Biotechnologies raised USD 25. 000 mn in Seed funding led by Sutter Hill Ventures, with participation from Overlap Holdings and other investors. The total amount raised to date is USD 25.

000 mn. The founder's specific history is not disclosed, but the company has established itself as an innovative player in the biotechnology sector. Ridge Biotechnologies specializes in AI-driven enzyme and targeted drug design, focusing on creating novel therapeutics that address complex medical challenges. Their product offerings include NativeLink enzymes, facilitating site-specific modification of proteins and peptides, and ProTrigger linkers that activate and release therapeutic payloads, reducing off-target toxicity in cancer therapy.

The NativeLink – AXC product enables stable linkages in antibody-drug conjugates, enhancing therapeutic indices. Ridge Biotechnologies serves biopharmaceutical companies and research institutions mainly in North America and Europe, aiming to improve patient outcomes through advanced biotechnology solutions. Ridge Biotechnologies generates revenue through strategic partnerships and collaborations with pharmaceutical companies and research organizations seeking innovative drug development solutions. These involve customized agreements that allow clients to access Ridge's proprietary technologies and services, such as enzyme functionalization and targeted drug delivery systems.

The flagship products, including NativeLink – AXC and ProTrigger linkers, add significant value in creating advanced therapeutics. Revenue is primarily derived from B2B relationships, enabling clients to leverage Ridge's proprietary platforms to enhance drug development processes. Looking ahead, Ridge Biotechnologies plans to expand its product offerings, focusing on enzyme-based therapeutic design and deploying a machine learning drug development platform. The recent Seed funding of USD 25.

000 mn will support the establishment of the therapeutic design infrastructure and the expansion of their antibody conjugate product line. The company aims to target new markets within the biopharmaceutical field, particularly in North America and Europe, by enhancing their service offerings and technological capabilities by 2026.